Epoetin beta therapy in patients with solid tumours

Critical Reviews in Oncology/Hematology

Volumn 58, Issue 1, 2006, Pages 46-52

  Pronzato, Paolo ^a   Jassem, Jacek ^b   Mayordomo, Jose ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Anaemia; Cancer; Epoetin beta; Survival

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER SURVIVAL; DISEASE MANAGEMENT; DRUG EFFICACY; DRUG SAFETY; HUMAN; QUALITY OF LIFE; SOLID TUMOR; TUMOR GROWTH;

EID: 33644941774     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.08.010     Document Type: Review

References (46)

1. J.E. Groopman, and L.M. Itri Chemotherapy-induced anemia in adults: incidence and treatment J Natl Cancer Inst 91 1999 1616 1634
2. K. Knight, S. Wade, and L. Balducci Prevalence and outcomes of anemia in cancer: a systematic review of the literature Am J Med 116 Suppl. 7A 2004 11S 26S
3. H. Ludwig, S. Van Belle, and P. Barrett-Lee The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients Eur J Cancer 40 2004 2293 2306
4. D. Cella Factors influencing quality of life in cancer patients: anemia and fatigue Semin Oncol 25 Suppl. 7 1998 43 46
5. J. Lutterbach, and R. Guttenberger Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx Int J Radiat Oncol Biol Phys 48 2000 1345 1350
6. J.J. Caro, M. Salas, A. Ward, and G. Goss Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review Cancer 91 2001 2214 2221
7. C. Bokemeyer, K. Oechsle, and J.T. Hartmann Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer Br J Cancer 87 2002 1066 1071
8. L.M. Williamson, S. Lowe, and E.M. Love Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports BMJ 319 1999 16 19
9. P.D. Jensen, F.T. Jensen, T. Christensen, J.L. Nielsen, and J. Ellegaard Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias Blood 101 2003 91 96
10. M. Cazzola, Y. Beguin, J. Kloczko, I. Spicka, and B. Coiffier Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production Br J Haematol 122 2003 386 393
11. C. Oberhoff, B. Neri, and D. Amadori Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study Ann Oncol 9 1998 255 260
12. J. Bogdanos, D. Karamanolakis, and K. Milathianakis Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases Anticancer Res 24 2004 1957 1962
13. A. Österborg, Y. Brandberg, and V. Molostova Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J Clin Oncol 20 2002 2486 2494
14. M. Boogaerts, B. Coiffier, and C. Kainz Impact of epoetin beta on quality of life in patients with malignant disease Br J Cancer 88 2003 988 995
15. A.M. Olsson, J.H. Svensson, and J. Sundstrom Erythropoietin treatment in metastatic breast cancer-effects on Hb, quality of life and need for transfusion Acta Oncol 41 2002 517 524
16. B. Glimelius, T. Linne, and K. Hoffman Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer J Clin Oncol 16 1998 434 440
17. D. Hardut, K. Wiesenberger, W. Minar, and R. Pirker Epoetin beta in patients with lung cancer receiving chemotherapy Lung Cancer 41 Suppl. 2 2003 264 [abstract P682]
18. A. Ordóñez, D. Isla, A. Sánchez, A. Arrivi, and J.L. Manzano Prevention of anaemia in patients with solid tumours receiving platinum-based chemotherapy: the NeoPrevent study Ann Oncol 15 Suppl. 3 2004 [abstract 843P]
19. J. Bogdanos, D. Karamanolakis, K. Milathianakis, P. Repousis, A. Tsintavis, and M. Koutsilieris Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement Anticancer Res 23 2003 1757 1762
20. B. Modder, J.E. Foley, and J.W. Fisher The in vitro and in vivo effects of testosterone and steroid metabolites on erythroid colony forming cells (CFU-E) J Pharmacol Exp Ther 207 1978 1004 1012
21. J. Crawford, D. Cella, and C.S. Cleeland Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888 895
22. C. Bokemeyer, M.S. Aapro, and A. Courdi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer Eur J Cancer 40 2004 2201 2216
23. R. MacRae, Y. Shyr, and D. Johnson Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant Radiother Oncol 64 2002 37 40
24. O. Hansen, M. Nielsen, and K.A. Werenberg The impact of hemoglobin (Hb) value on the outcome of radical radiotherapy (RT) in locally advanced NSCLC Lung Cancer 41 Suppl. 2 2003 136 [abstract P180]
25. W.W. ten Bokkel Huinink, C.A.M. de Swart, and D.W. van Toorn Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy Med Oncol 15 1998 174 182
26. M. Boogaerts, C. Oberhoff, and W. ten Bokkel Huinink Epoetin beta (NeoRecormon) therapy in anaemic cancer patients receiving platinum and non-platinum chemotherapy Haematologica/Hematol J 90 Suppl. 2 2005 438 [abstract 1134]
27. B. Coiffier, J.P. Guastalla, and E. Pujade-Lauraine Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey Eur J Cancer 37 2001 1617 1623
28. P.J. Barrett-Lee, H. Ludwig, and C. Bokemeyer Independent risk factors for anemia in cancer (CA) patients (pts) are defined by logistic regression modeling: Results from the European Cancer Anaemia Survey (ECAS) Proc Am Soc Clin Oncol 22 2003 733 [abstract 2946]
29. D. Antonadou, E. Cardamakis, M. Puglisi, N. Malamos, and N. Throuvalas Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies Eur J Cancer 37 Suppl. 6 2001 144 [abstract 530]
30. C.M. Glaser, W. Millesi, and G.V. Kornek Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int J Radiat Oncol Biol Phys 50 2001 705 715
31. T.J. Littlewood, E. Bajetta, J.W. Nortier, E. Vercammen, B. Rapoport Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
32. J. Vansteenkiste, R. Pirker, and B. Massuti Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
33. R. Pirker, J. Vansteenkiste, J. Gateley, D. Tomita, G. Rossi, and J. Musil Results of a phase 3, randomized, double-blind study indicate that darbepoetin alfa decreases RBC transfusions and increases health-related quality of life in comparison with placebo Hematol J 3 Suppl. 1 2002 352 [abstract 1189]
34. J.U. Blohmer, F. Wurschmidt, and U. Petry Sixth interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for pts with high-risk cervical cancer Proc Am Soc Clin Oncol 22 2003 [abstract 1798]
35. A. Larsson, G. Landberg, S. Påhlman, and M. Albertsson Erythropoietin enhances response to treatment in patients with advanced breast cancer Acta Oncol 43 2004 594 597
36. M. Henke, R. Laszig, and C. Rube Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
37. J. Glaspy, and J. Dunst Can erythropoietin therapy improve survival? Oncology 37 Suppl. 1 2004 5 11
38. P. Vaupel, J. Dunst, and A. Engert Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia Onkologie 28 2005 216 221
39. A. Becker, P. Stadler, and R.S. Lavey Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas Int J Radiat Oncology Biol Phys 46 2000 459 466
40. P. Vaupel, O. Thews, A. Mayer, S. Hockel, and M. Hockel Oxygenation status of gynaecologic tumors: what is the optimal haemoglobin level? Strahlenther Onkol 178 2002 727 731
41. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 2003 459 460
42. M. Aapro, J. Dunst, J.F. Morère, M.R. Nowrousian, M. Huber, and H.U. Burger Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies Ann Oncol 15 Suppl. 3 2004 [abstract 841P]
43. J. Bohlius, S. Langensiepen, and G. Schwarzer Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 97 2005 489 498
44. A.Y. Lee, and M.N. Levine Venous thromboembolism and cancer: risks and outcomes Circulation 107 Suppl. 1 2003 I17 I21
45. B. Coiffier, M. Boogaerts, and M. Aapro Thromboembolic events in patients with cancer treated with epoetin beta: a meta-analysis of controlled clinical trials Ann Oncol 15 Suppl. 3 2004 [abstract 840P]
46. R.C. Leonard, M. Aapro, and S. Chan Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy Ann Oncol 15 Suppl. 3 2004 [abstract 188P]